File 06 - questions on the record
Thymosin Alpha-1: straight answers to the questions people actually ask.
Direct, cited, and honest about what the evidence does and does not show.
Who should not take thymosin alpha 1?
The literature flags theoretical cautions rather than firm prohibitions: people with active autoimmune disease (it stimulates effector immunity) [10] and solid-organ transplant recipients (it could counter intentional immunosuppression) [5] warrant caution, and pregnancy and lactation are uncharacterized [6]. None of this is settled by a trial. It is also not FDA-approved in the US [6].
How does thymosin alpha 1 make you feel?
Honestly, most people feel nothing, and that is expected - it is an immune modulator that acts in your bloodwork, not a stimulant or sedative you sense [9]. Reported impressions skew toward fewer or shorter colds and faster recovery when run-down, which are anecdotal, not measured [9]. The most common physical note is mild injection-site redness or stinging [9].
Is thymosin alpha 1 safe to take?
In studied, regulated use it has a benign profile: across 600,000+ patients the dominant adverse event is mild injection-site reaction, with no documented organ toxicity [9]. The real risks are theoretical cautions in autoimmunity and transplant [5][10] and, separately, the quality of unregulated research-grade material, since it is not FDA-approved in the US [6]. This is not medical advice.
Any side effects from thymosin alpha 1 injections?
The most common is mild redness, itching, or brief stinging at the injection site, which usually settles on its own [9]. A minority report a short-lived flu-like or achy day early in a course, and a few mention a low-grade headache or tiredness [9]. Large surveillance data identifies local reactions as the dominant event with no organ toxicity at studied doses [9].
What are the side effects of thymosin alpha 1?
Injection-site reactions (redness, itching, burning) lead the list, with occasional transient flu-like symptoms, across post-marketing surveillance of more than 600,000 treated patients and a 2024 trial review - and no documented organ toxicity at studied doses [9]. Beyond that, the cautions are theoretical (autoimmunity, transplant) [5][10] and pregnancy data is absent [6].
What is thymosin alpha 1?
Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus (thymosin fraction 5); Goldstein and colleagues purified it and determined its complete sequence in 1977 [1]. In the body it is cleaved from the larger precursor prothymosin alpha [1]. The synthetic, sequence-identical drug version is called thymalfasin [4].
What does thymosin alpha 1 do?
It modulates immunity at the innate-adaptive interface: it signals through TLR2/TLR9 on dendritic cells to mature them and matures T-cells toward a Th1 response, while also activating IDO to generate regulatory T-cells [5]. The result is dual - restoring quiet immunity while damping overactive immunity. It is not anabolic and does not build muscle [5].
What is thymosin alpha 1 used for?
Abroad, as the generic thymalfasin, it is used mainly for chronic hepatitis B and as an immune adjuvant [4]. It has also been studied as an immunostimulatory adjuvant in cancer (melanoma, hepatocellular carcinoma, lung cancer), acting through dendritic cells and potentially mitigating checkpoint-inhibitor toxicity [7]. It is not FDA-approved for any use in the US [6].
Is thymosin alpha 1 FDA-approved?
No. Thymosin Alpha-1 (generic name thymalfasin) is not FDA-approved for marketing in the United States; US availability is limited to investigational and compounding contexts [6]. It is approved as a drug in roughly 35 other countries [6]. The FDA also evaluated related bulk substances for compounding without endorsing them [6].
What is TA1 peptide?
TA1 (also written Tα1) is just shorthand for Thymosin Alpha-1 - the same 28-amino-acid acetylated thymic peptide, cleaved in the body from prothymosin alpha and sold abroad in synthetic form as thymalfasin [1][4]. The various names (TA-1, Tα1, thymosin alpha 1, thymalfasin) all point to one molecule [4].
Is TB-500 the same as thymosin alpha 1?
No - different molecule entirely. TB-500 is thymosin beta-4, a 43-amino-acid actin-binding peptide studied for tissue repair, and it is the one on the WADA prohibited list. Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide cleaved from prothymosin alpha [1]. Different sequence, size, mechanism, and use [5].
How long should you take thymosin alpha 1?
There is no US-approved schedule to cite. In the research, durations vary by setting: the marketed hepatitis regimen is 1.6 mg subcutaneous twice weekly (reported as study/approved-abroad data), sepsis trials ran five to seven days, and one cancer adjunct study ran weekly for up to 12 months [4][3][7]. This is research context, not a recommendation.
How long does it take for thymosin alpha 1 to work?
The literature does not define a reliable 'time to effect' for individuals - outcomes are measured over weeks of dosing in trials, not days [6]. Pharmacokinetically the peptide itself is short-lived (elimination half-life roughly 2 hours), so any effect reflects repeated immune signaling over a course, not a single dose [12]. Many people report no perceptible effect at all [9].
What is the dosing protocol for thymosin alpha 1?
Reported as research data only: the most-cited regimen is 1.6 mg subcutaneous twice weekly for chronic hepatitis (the thymalfasin schedule) [4]; sepsis RCTs used 1.6 mg every 12 hours for five to seven days [2][3]; the single-dose research range is 0.8-6.4 mg [6]. There is no FDA-approved US protocol and no validated self-use dose [6].
How much thymosin alpha 1 should I take?
This site does not give human dosing. The research records doses only by population and route - for example 1.6 mg subcutaneous twice weekly in hepatitis trials and a 0.8-6.4 mg single-dose range across studies [4][6]. Because it is not an approved US drug, there is no validated dose for personal use [6]. Treat any number here as study data, not instruction.
When is the best time to take thymosin alpha 1?
The trials do not establish an optimal time of day; they specify a route (subcutaneous) and a frequency (for example twice weekly, or every 12 hours in sepsis), not a clock time [4][3]. With an elimination half-life of roughly 2 hours, the schedule's frequency matters more than timing [12]. No timing recommendation is given here.
Does thymosin alpha 1 help cancer?
It has been studied as an immunostimulatory adjuvant - not a standalone treatment - alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, where it may help 'turn a cold tumour hot' and reduce checkpoint-inhibitor toxicity [7]. This is a combination-protocol role in the research literature, not an approved US cancer therapy [7].
Is thymosin alpha 1 worth it?
That is a value judgment we will not make for you, but here is the honest evidence backdrop: the strongest signal is in chronic viral hepatitis, the trial base is heterogeneous and often single-region, and the largest rigorous sepsis trial (TESTS, 1,106 adults) was null - HR 0.99, P=0.93 [3]. It is also not FDA-approved in the US [6].
Does thymosin affect aging?
Endogenous Thymosin Alpha-1 levels decline with age, and the peptide has been studied as a vaccine adjuvant aimed at countering immunosenescence (the age-related weakening of immunity) [1][7]. But there is no controlled evidence that taking it slows aging or extends lifespan; the immune-restorative framing is mechanistic and indication-specific, not an anti-aging claim.
Does thymosin alpha 1 reduce the mortality of severe COVID-19?
A retrospective review of 76 severe COVID-19 patients associated Thymosin Alpha-1 with lower mortality (11.11% vs 30.00%, P=0.044) and restored exhausted T-cells [6]. But that study is retrospective, and a later systematic review of about 5,300 patients found no statistically significant overall mortality benefit. The signal is encouraging and unproven, not established.
Has anyone tried thymosin alpha 1 for chronic illness or immune issues?
Yes - it is widely discussed for immune support and post-viral fatigue, and reported impressions include fewer infections and steadier energy during recovery [9]. Those are anecdotal, not clinical evidence, and a vague 'feeling more resilient' is highly subjective [9]. Self-experimenting can also mask a treatable underlying condition that deserves real evaluation [6].
Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?
They are different molecules. Thymosin Alpha-1 is a 28-amino-acid acetylated immunomodulatory peptide cleaved from prothymosin alpha, acting on dendritic cells and T-cells [1][5]. Thymosin beta-4 (TB-500) is a 43-amino-acid actin-binding peptide studied for tissue repair, and it - not Thymosin Alpha-1 - is on the WADA prohibited list [5].